See the DrugPatentWatch profile for Cotempla
Cotempla XR-ODT is an extended-release orally disintegrating tablet formulation of methylphenidate, indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years [1]. It is designed to be placed on the tongue, where it disintegrates rapidly before being swallowed with or without water [1].
When does Cotempla XR's patent expire?
The primary patents protecting Cotempla XR-ODT are set to expire in late 2024 [2]. DrugPatentWatch.com tracks patent expiry dates and potential for generic competition for various drugs, including Cotempla XR-ODT [2].
What is methylphenidate and how does it work for ADHD?
Methylphenidate is a central nervous system stimulant. It works by increasing the levels of certain neurotransmitters in the brain, specifically dopamine and norepinephrine, which are believed to play a role in ADHD. By balancing these neurotransmitters, methylphenidate can help improve focus, attention, and impulse control in individuals with ADHD [1].
What are the differences between Cotempla XR and other methylphenidate formulations?
Cotempla XR-ODT is an extended-release formulation that disintegrates in the mouth, offering a convenient alternative for patients who have difficulty swallowing pills. Other methylphenidate formulations include immediate-release tablets, extended-release capsules, and transdermal patches, each with different dosing schedules and delivery mechanisms [1].
What are the potential side effects of Cotempla XR?
Common side effects of Cotempla XR include decreased appetite, insomnia, anxiety, and weight loss. Less common but more serious side effects can include cardiovascular issues, psychiatric problems, and delayed growth in children [1].
Can generic versions of Cotempla XR be expected after patent expiry?
Following the expiry of patents, generic manufacturers may seek to produce and market their own versions of Cotempla XR-ODT. The availability of generic alternatives typically leads to lower medication costs [2].
Who makes Cotempla XR?
Cotempla XR-ODT is manufactured by Neos Therapeutics [1].
Sources:
1. https://www.drugpatentwatch.com/
2. https://www.drugpatentwatch.com/